Skip to main content
PharmaCielo Ltd. logo

PharmaCielo Ltd. — Investor Relations & Filings

Ticker · PCLO ISIN · CA71716K1012 LEI · 5493002XOFWMT83TYQ57 TSXV Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2020-05-04 Board/Management Inform…
Country CA Canada
Listing TSXV PCLO

About PharmaCielo Ltd.

https://www.pharmacielo.com/

PharmaCielo Ltd. is a global supplier specializing in the cultivation, processing, and distribution of medicinal-grade cannabis extracts and dried flower. The company focuses on ethical and sustainable production, aiming to be a leading partner in the global medicinal cannabis market. Utilizing ideal equatorial conditions, PharmaCielo operates large-scale, high-efficiency production facilities, including 12 hectares of open-air greenhouses, enabling four full crops annually for reliable supply. Its product portfolio includes standardized extracts, such as high-purity CBD Isolate, and both psychoactive and non-psychoactive derivatives. Production adheres to pharmaceutical-quality standards, supported by proprietary genetics maintained in a tissue culture lab and advanced processing facilities ensuring consistency and safety.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of a new senior executive (President) at PharmaCielo Ltd. It details the background of the appointee, his role, and stock options granted. There is no financial data, no detailed financial report, no earnings summary, no regulatory filing, or other report type content. The document is an announcement of a management change, specifically the appointment of a senior leader to the executive team. This fits the category of Board/Management Information (MANG). The document length is 8024 characters, which is sufficient for a detailed announcement but does not contain financial statements or other report content. Therefore, the correct classification is MANG with high confidence.
2020-05-04 English
News release - English.pdf
Regulatory Filings
2020-04-30 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CEO. It certifies the review and fair presentation of annual filings for the financial year ended December 31, 2019. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references annual filings but does not include them. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than as the actual annual report (10-K) or other financial reports.
2020-04-30 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CFO of PharmaCielo Ltd. It certifies the review and fair presentation of the annual filings for the financial year ended December 31, 2019. The document is primarily an officer certification letter confirming the accuracy and completeness of the annual filings, without containing actual financial statements or substantive financial data. It explicitly states it is a certification under National Instrument 52-109 and does not include the full annual report or financial statements. According to the CERTIFICATION RULE, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the Annual Report (10-K) or other financial reports.
2020-04-30 English
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management's Discussion and Analysis For the year ended December 31, 2019' and contains detailed management commentary on the company's financial condition, operational highlights, key developments, and forward-looking statements. It references the audited consolidated financial statements for the year ended December 31, 2019, and discusses business trends, operational adjustments, and strategic initiatives. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content aligns with the typical Management Discussion and Analysis (MD&A) section that accompanies annual or interim financial reports, providing management's detailed explanation of financial results and business outlook. Therefore, the document fits the category of Management Reports (MDA).
2020-04-30 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 13-501F1, which is a management certification related to participation fees for reporting issuers, submitted to the Alberta Securities Commission. It includes certification by an officer (Chief Financial Officer) confirming the accuracy of the information provided, market value calculations for securities, and fee payment details. The document is primarily a certification and fee calculation form rather than a financial report or detailed management discussion. It does not contain comprehensive financial statements or substantive financial analysis. Therefore, it fits the criteria for a Regulatory Filing (RNS) as it is a regulatory compliance document and officer certification rather than a full report or announcement.
2020-04-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.